The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Flagged first, then by citations
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 601–700 of 1,002
Chemical Composition of Commercial Cannabis
Wishart, D. S., Hiebert-Giesbrecht, M. R., Inchehborouni, G., Cao, X., Guo, A. C., LeVatte, M., Torres-Calzada, C., Gautam, V., Johnson, M., Liigand, J., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06616 · Cited by 33
Mechanism-based nonopioid analgesic targets
Zeng, X., Powell, R., & Woolf, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191346 · Cited by 35
Biosynthesis and Pharmacology of Phytocannabinoids and Related Chemical Constituents
Thomas, B. F., & ElSohly, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-804646-3.00002-3 · Cited by 32
Impact of cannabis legalization on treatment and research priorities for cannabis use disorder
Sahlem, G. L., Tomko, R. L., Sherman, B. J., Gray, K. M., & McRae‐Clark, A. L. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1465398 · Cited by 32
Smoking as a Risk Factor of Invasive Fungal Disease: Systematic Review and Meta-Analysis
Pourbaix, A., Rapnouil, B. L., Guéry, R., Lanternier, F., Lortholary, O., & Cohen, J. F. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa001 · Cited by 29
Gaggiotti, S., Palmieri, S., Pelle, F. D., Sergi, M., Cichelli, A., Mascini, M., & Compagnone, D. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.127697 · Cited by 29
Schneider, J., Algharably, E. A. E., Budnick, A., Wenzel, A., Dräger, D., & Kreutz, R. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229229 · Cited by 29
Joffre, J., Yeh, C., Wong, E., Thete, M. V., Xu, F., Zlatanova, I., Lloyd, E., Kobzik, L., Legrand, M. M., & Hellman, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000213 · Cited by 29
Cannabis Use as a Risk Factor for Depression, Anxiety, and Suicidality
Halladay, J. E., MacKillop, J. M., Munn, C., Jack, S. M., & Georgiades, K. (2020) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000334 · Cited by 36
Neuropathic Pain and Sickle Cell Disease: a Review of Pharmacologic Management
Orhurhu, M. S., Chu, R., Claus, L. E., Roberts, J. S., Salisu, B., Urits, I., Orhurhu, E., Viswanath, O., Kaye, A. D., Kaye, A. J., et al. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00885-5 · Cited by 28
Chiurchiù, E., Sampaolesi, S., Allegrini, P., Ciceri, D., Ballini, R., & Palmieri, A. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202001633 · Cited by 30
Abuhasira, R., Haviv, Y. S., Leiba, M., Leiba, A., Ryvo, L., & Novack, V. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.005 · Cited by 29
Nicolaou, A. G., Christodoulou, M. C., Stavrou, I. J., & Kapnissi‐Christodoulou, C. P. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462277 · Cited by 29
Nielsen, S. W., Ruhlmann, C. H. B., Eckhoff, L., Brønnum, D., Herrstedt, J., & Dalton, S. O. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06515-z · Cited by 29
Ergisi, M., Erridge, S., Harris, M., Kawka, M., Nimalan, D., Salazar, O., Loupasaki, K., Ali, R., Holvey, C., Coomber, R., et al. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0145 · Cited by 29
Mills, L., Lintzeris, N., O'Malley, M., Arnold, J. C., & McGregor, I. S. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13444 · Cited by 30
The effect of medical cannabis on cognitive functions: a systematic review
Wieghorst, A., Roessler, K. K., Hendricks, O., & Andersen, T. E. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02073-5 · Cited by 32
The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives
Isaac, S., Saini, B., & Chaar, B. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155113 · Cited by 29
Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders
Noel, C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.029 · Cited by 29
The Achilles Heel of Medical Cannabis Research—Inadequate Blinding of Placebo-Controlled Trials
Casarett, D. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.5308 · Cited by 29
Contemporary Routes of Cannabis Consumption: A Primer for Clinicians
Peters, J., & Chien, J. (2018) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2018.020 · Cited by 29
Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms
Casarett, D., Beliveau, J., & Arbus, M. S. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0658 · Cited by 33
Trkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Moretta, P., Cavallo, N. D., Candia, C., Lanzillo, A., Marcuccio, G., Santangelo, G., Marcuccio, L., Ambrosino, P., & Maniscalco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216418 · Cited by 36
Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks
Johnson, B. W., Strand, N. H., Raynak, J., Jara, C., Habtegiorgis, K., Hand, B. A., Hong, S., & Maloney, J. A. (2025) · Biomedicines · doi:10.3390/biomedicines13030530 · Cited by 31
Gilles de la Tourette syndrome – A treatable condition?
Hartmann, A., Martino, D., & Murphy, T. L. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2016.07.004 · Cited by 28
Cannabinoids in the treatment of rheumatic diseases: Pros and cons
Sarzi‐Puttini, P., Ablin, J. N., Trabelsi, A., Fitzcharles, M., Marotto, D., & Häuser, W. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102409 · Cited by 31
Medicinal Cannabis in Orthopaedic Practice
Kleeman-Forsthuber, L. T., Dennis, D. A., & Jennings, J. M. (2019) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-19-00438 · Cited by 28
The effects of delta-9-tetrahydrocannabinol (THC) on inflammation: A review
Miller, H. P., Bonawitz, S. C., & Ostrovsky, O. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104111 · Cited by 28
High performance thin-layer chromatography (HPTLC) analysis of cannabinoids in cannabis extracts
Liu, Y., Brettell, T. A., Victoria, J., Wood, M. R., & Staretz, M. E. (2020) · Forensic Chemistry · doi:10.1016/j.forc.2020.100249 · Cited by 28
Cannabinoids and orthopedic surgery: a systematic review of therapeutic studies
Vivace, B. J., Sanders, A. N., Glassman, S. D., Carreon, L. Y., Laratta, J. L., & Gum, J. L. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02205-y · Cited by 28
Cannabis against chronic musculoskeletal pain: a scoping review on users and their perceptions
Furrer, D., Kröger, E., Marcotte, M., Jauvin, N., Bélanger, R. E., Ware, M. A., Foldes‐Busque, G., Aubin, M., Pluye, P., & Dionne, C. E. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00096-8 · Cited by 30
Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell
Qi, X., Liu, C., Li, G., Luan, H., Li, S., Yang, D., & Zhou, Z. (2021) · Journal of Dentistry · doi:10.1016/j.jdent.2021.103673 · Cited by 28
LeBlanc, R., Bergstrom, D. J., Côté, J. A., Kotb, R. R., Louzada, M., & Sutherland, H. J. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.028 · Cited by 29
Sphingolipid and Endocannabinoid Profiles in Adult Attention Deficit Hyperactivity Disorder
Brunkhorst-Kanaan, N., Trautmann, S., Schreiber, Y., Thomas, D., Kittel‐Schneider, S., Gurke, R., Geißlinger, G., Reif, A., & Tegeder, I. (2021) · Biomedicines · doi:10.3390/biomedicines9091173 · Cited by 28
Wang, Y., Jacques, J., Li, Z., Sibille, K. T., & Cook, R. (2021) · Cannabis · doi:10.26828/cannabis/2021.02.006 · Cited by 29
Kim, J., Choi, H., Kang, E. K., Ji, G. Y., Kim, Y., & Choi, I. S. (2021) · Molecules · doi:10.3390/molecules26196077 · Cited by 30
Chaffee, B. W., Halpern‐Felsher, B. L., & Cheng, J. (2021) · Community Dentistry And Oral Epidemiology · doi:10.1111/cdoe.12721 · Cited by 28
Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond
Hempel, B. J., & Xi, Z. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.006 · Cited by 29
Exploration of Multiverse Activities of Endocannabinoids in Biological Systems
Behl, T., Makkar, R., Sehgal, A., Singh, S., Makeen, H. A., Albratty, M., Alhazmi, H. A., Meraya, A. M., & BUNGAU, S. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105734 · Cited by 29
Biosynthetic origins of unusual cannabimimetic phytocannabinoids in Cannabis sativa L: A review
Welling, M. T., Deseo, M. A., Bacic, A., & Doblin, M. S. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113282 · Cited by 29
Medical Cannabis in the Palliation of Malignant Wounds—A Case Report
Maida, V. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.09.003 · Cited by 28
A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol
Sultan, S. R., Millar, S., O’Sullivan, S. E., & England, T. J. (2018) · Pharmaceuticals · doi:10.3390/ph11010013 · Cited by 29
Cannabis for medical and scientific purposes: the Colombian landscape
Sánchez, P. A. C. (2020) · Colombian Journal of Anesthesiology · doi:10.5554/22562087.e954 · Cited by 27
Healy, C. R., Gethin, G., Pandit, A. S., & Finn, D. P. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115714 · Cited by 32
Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review
Mohammed, S. Y. M., Leis, K., Mercado, R. E., Castillo, M. M. S., Miranda, K. J., & Carandang, R. R. (2023) · Pain Management Nursing · doi:10.1016/j.pmn.2023.10.002 · Cited by 27
Monitoring Marijuana Use in the United States
Azofeifa, A., Mattson, M. E., & Grant, A. M. (2016) · JAMA · doi:10.1001/jama.2016.13696 · Cited by 27
Pergolizzi, J. V., Taylor, R., LeQuang, J. A., Zampogna, G., & Raffa, R. B. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3257-1 · Cited by 27
Assessment of Norwegian physicians’ knowledge, experience and attitudes towards medical cannabis
Arnfinsen, J. L., & Kısa, A. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1806208 · Cited by 27
Potential Role of Cannabidiol on Sports Recovery: A Narrative Review
Rojas‐Valverde, D. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.722550 · Cited by 32
Bowen, J. K., Chaparro, J. M., McCorkle, A. M., Palumbo, E., & Prenni, J. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-01378-0 · Cited by 27
Medical marijuana and pain management
Temple, L. M. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.05.014 · Cited by 25
Herzog, S., Shanahan, M., Grimison, P., Tran, A. D., Wong, N., Lintzeris, N., Simes, R. J., Stockler, M. R., & Morton, R. L. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0565-6 · Cited by 27
Efficacy of Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review
McConachie, S. M., Caputo, R. A., Wilhelm, S. M., & Kale-Pradhan, P. B. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019852601 · Cited by 28
Vin-Raviv, N., Akinyemiju, T., Meng, Q., Sakhuja, S., & Hayward, R. (2016) · Cancer Medicine · doi:10.1002/cam4.968 · Cited by 21
Faiz, M. B., Naeem, F., Irfan, M., Aslam, M. A., Estevinho, L. M., Ateşşahin, D. A., Alshahrani, A. M., Călina, D. C., Khan, K., & Sharifi‐Rad, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01356-8 · Cited by 28
Gruber, S. A., & Sagar, K. A. (2017) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/2372732216684851 · Cited by 28
Ballas, S. K. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0011 · Cited by 26
Should Oncologists Recommend Cannabis?
Abrams, D. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0659-9 · Cited by 22
Self-Efficacy in Researching and Obtaining Medical Cannabis by Patients With Chronic Conditions
Brady, J. P., Bruce, D., Foster, E., & Shattell, M. M. (2020) · Health Education & Behavior · doi:10.1177/1090198120914249 · Cited by 26
Turna, J., Balodis, I. M., Ameringen, M. V., Busse, J. W., & MacKillop, J. M. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0088 · Cited by 27
Trends in intellectual property rights protection for medical cannabis and related products
Wyse, J. W., & Luria, G. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-020-00057-7 · Cited by 26
Oultram, J. M. J., Pegler, J. L., Bowser, T. A., Ney, L. J., Eamens, A. L., & Grof, C. P. L. (2021) · Biomedicines · doi:10.3390/biomedicines9030234 · Cited by 30
Casey, S. L., Mitchell, V. A., Sokolaj, E. E., Winters, B. L., & Vaughan, C. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158649 · Cited by 29
Preoperative Evaluation of the Patient with Substance Use Disorder and Perioperative Considerations
Pulley, D. D. (2016) · Anesthesiology Clinics · doi:10.1016/j.anclin.2015.10.015 · Cited by 26
Jambo, H., Dispas, A., Avohou, H. T., André, S., Hubert, C., Lebrun, P., Ziémons, E., & Hubert, P. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.05.049 · Cited by 26
der Medizin“, A.-H.-K. D. D. S. „. I., Petzke, F. W., Karst, M., Gastmeier, K., Radbruch, L., Steffen, E., & Häuser, W. (2019) · Der Schmerz · doi:10.1007/s00482-019-00407-2 · Cited by 25
Andrews, C. N., Devlin, S. M., Le Foll, B., Fischer, B., Tse, F., Storr, M., & Congly, S. E. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy064 · Cited by 25
"Considerations for the Use of Medical Cannabis: An Overview of Benefits and Harms"
Shakya, D. R. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.36.005886 · Cited by 8
Cannabinoids in the Management of Musculoskeletal Pain
Madden, K., van der Hoek, N., Chona, S., George, A., Dalchand, T., Baldawi, H., Mammen, G., & Bhandari, M. (2018) · JBJS Reviews · doi:10.2106/jbjs.rvw.17.00153 · Cited by 25
A Survey on the Medical Use of Cannabis in Europe: A Position Paper
Bramness, J. G., Dom, G., Gual, A., Mann, K. F., & Wurst, F. M. (2018) · European Addiction Research · doi:10.1159/000492757 · Cited by 25
Marijuana Use and Potential Implications of Marijuana Legalization
Grigsby, T. M., Hoffmann, L. M., & Moss, M. J. (2020) · Pediatrics in Review · doi:10.1542/pir.2018-0347 · Cited by 25
Gibbard, M., Mount, D., Rassekh, S. R., & Siden, H. B. (2021) · CMAJ Open · doi:10.9778/cmajo.20200212 · Cited by 28
Hallinan, C. M., Khademi, S., Conway, M., & Bonomo, Y. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0269143 · Cited by 24
Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection
Siqueira, A. L. G. D. B., Cremasco, P. V. V., Bahú, J. O., da Silva, A. P., de Andrade, L. R. M., González, P., Crivellin, S., Concha, V. O. C., Krambeck, K., Lodi, L., et al. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.08.006 · Cited by 25
Feingold, D., Rehm, J., Factor, H., Redler, A., & Lev‐Ran, S. (2018) · Depression and Anxiety · doi:10.1002/da.22735 · Cited by 24
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25
Laaboudi, F.-Z., Rejdali, M., Amhamdi, H., Salhi, A., Elyoussfi, A., & Ahari, M. (2024) · Toxicology Reports · doi:10.1016/j.toxrep.2024.101685 · Cited by 26
Merlin, J. S., Long, D. M., Becker, W. C., Cachay, E. R., Christopolous, K., Claborn, K., Crane, H. M., Edelman, E. J., Lovejoy, T. I., Mathews, W. C., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001998 · Cited by 24
Dong, W., Liang, J., Barnett, I., Kline, P. C., Altman, E., & Zhang, M. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02200-7 · Cited by 24
Dei, M., Casagni, E., Casiraghi, A., Minghetti, P., Fornasari, D., Ferri, F., Arnoldi, S., Gambaro, V., & Roda, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.570616 · Cited by 24
Schräder, N. H. B., Gorell, E. S., Stewart, R. E., Duipmans, J. C., Harris, N., Pérez, V. A. F., Tang, J. Y., Wolff, A. P., & Bolling, M. C. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02010-0 · Cited by 25
Resveratrol Inhibition of the WNT/β-Catenin Pathway following Discogenic Low Back Pain
Genovese, T., Impellizzeri, D., D’Amico, R., Cordaro, M., Peritore, A. F., Crupi, R., Gugliandolo, E., Cuzzocrea, S., Fusco, R., Siracusa, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084092 · Cited by 24
Aviram, J., Lewitus, G. M., Vysotski, Y., Amna, M. A., Ouryvaev, A., Procaccia, S., Cohen, I., Leibovici, A., Akria, L., Goncharov, D., et al. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.861037 · Cited by 26
Almaraz, E. R., & Butowski, N. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01047-y · Cited by 25
Unveiling the angiogenic effects of cannabinoids: Enhancers or inhibitors?
Maia, J., Fonseca, B. M., Teixeira, N. A. A., & Correia‐da‐Silva, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115686 · Cited by 24
Cannabis use among recently treated cancer patients: perceptions and experiences
Salz, T., Meza, A. M., Chino, F. L., Mao, J. J. J., Raghunathan, N. J., Jinna, S., Brens, J., Furberg, H. F., & Korenstein, D. R. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07994-y · Cited by 24
Kovacic, K. K., & Lorenzo, C. D. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001076 · Cited by 24
Benefits and adverse effects of cannabis use among adults with persistent pain
Bigand, T. L., Anderson, C. L., Roberts, M. L. A., Shaw, M. R., & Wilson, M. (2018) · Nursing Outlook · doi:10.1016/j.outlook.2018.12.014 · Cited by 24
Anti-inflammatory mechanisms of cannabinoids: an immunometabolic perspective
van Niekerk, G., Mabin, T., & Engelbrecht, A. (2019) · Inflammopharmacology · doi:10.1007/s10787-018-00560-7 · Cited by 24
Ensuring access to safe, effective, and affordable cannabis‐based medicines
Martin, J. H., Hall, W., Fitzcharles, M., Borgelt, L. M., & Crippa, J. A. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14242 · Cited by 25
Dudeney, J., Sharpe, L., McDonald, S., Menzies, R. E., & McGuire, B. (2022) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14260 · Cited by 26
Morris, D. H., Davis, A. K., Lauritsen, K. J., Rieth, C. M., Silvestri, M. M., Winters, J. J., & Chermack, S. T. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.08.005 · Cited by 26
Banister, S. D., Kumar, K. K., Kumar, V., Kobilka, B. K., & Malhotra, S. V. (2019) · MedChemComm · doi:10.1039/c8md00595h · Cited by 22
Cannabis-based medicines and the perioperative physician
Tapley, P., & Kellett, S. (2019) · Perioperative Medicine · doi:10.1186/s13741-019-0127-x · Cited by 25
Prescribing medical cannabis: ethical considerations for primary care providers
Glickman, A., & Sisti, D. A. (2019) · Journal of Medical Ethics · doi:10.1136/medethics-2019-105759 · Cited by 23
When ESKD complicates the management of pain
Jhamb, M., Tucker, L., & Liebschutz, J. M. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12881 · Cited by 22
The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
Andradas, C., Truong, A., Byrne, J., & Endersby, R. (2021) · Cancers · doi:10.3390/cancers13010157 · Cited by 26
Vallée, A. (2023) · Scientific Reports · doi:10.1038/s41598-022-22841-6 · Cited by 23
Ghosh, D., Chaudhary, N., Shanker, K., Kumar, B., & Kumar, N. (2023) · Journal of Applied Research on Medicinal and Aromatic Plants · doi:10.1016/j.jarmap.2023.100476 · Cited by 23
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
